ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ifebemtinib

Also written as “IN10018”, “BI 853520” and “IN10018 in combination with PLD”.

Its studies are mostly in Ovarian Neoplasms · Neoplasms · Pancreatic Neoplasms · Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung, led by 5 companies.

Drug pageIfebemtinib: every studyMany companies study it; this page follows only the 16 they lead. All 16 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Aug 29, 202516 company-led studies, 10 open or runningNext primary completion: Mar 24, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
InxMed (Shanghai)117 open or runningphase 3since Aug 29, 2025Sep 26, 2019Mar 24, 2027phase 2 · NCT06014528
Boehringer Ingelheimits history only20 open or runningphase 1since Apr 7, 2011Apr 7, 2011none ahead
Hangzhou Hanx Biopharmaceuticalsits history only11 open or runningphase 2since Nov 25, 2024Nov 25, 2024Dec 31, 2027phase 2 · NCT06708663
InventisBioits history only11 open or runningphase 2since May 13, 2022May 13, 2022Dec 31, 2027phase 2 · NCT05379946
Shanghai Jeyou Pharmaceuticalits history only11 open or runningphase 3since Sep 13, 2026Sep 13, 2026Apr 2029phase 3 · NCT07833202
  • Named in fosun pharma’s own pipeline as IN10018 (FAK), phase 3, as of Sep 21, 2026 (source).

Also a collaborator on its studies: Ranok Therapuetics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Sep 26, 2019First study: phase 1 study in MelanomaFirst studyNCT04109456 · 51 enrolled · United States, Australia
  2. Mar 29, 2022Phase 1 study in Stomach NeoplasmsNCT05327231 · 33 enrolled · China
  3. Sep 15, 2022Phase 2 study in Platinum-resistant Ovarian CancerNCT05551507 · 150 enrolled · China
  4. Jan 19, 2023Named ifebemtinibINNProposed as its International Nonproprietary Name in WHO's List 128 · before, IN10018, BI 853520
  5. Mar 28, 20232 phase 2 studiesNCT05827796, NCT05830539
  6. Jul 13, 2023Phase 2 study in Solid TumorNCT05982522
  7. Aug 8, 20232 phase 2 studiesNCT05994131, NCT06014528
  8. Sep 1, 2023Phase 2 study in Small Cell Lung Cancer Extensive StageNCT06030258 · 120 enrolled · China
  9. Aug 29, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07174908 · 400 planned · China
  10. Feb 13, 2026Phase 2 study in Solid Tumor CancerNCT07441174 · 92 planned · China

Ahead

  1. Mar 24, 2027Primary completion: phase 2 study in Ovarian Cancer RecurrentNCT06014528
  2. Sep 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07174908
  3. Feb 28, 2031Primary completion: phase 2 study in Solid Tumor CancerNCT07441174

TargetBeta

PTK2 →read by rule
“An orally bioavailable inhibitor of the non-receptor, cytoplasmic tyrosine kinase protein tyrosine kinase 2 (focal adhesion kinase 1; FAK1; FAK: PTK2) ”NCIt, by rule
“Focal adhesion kinase 1 inhibitor”ChEMBL 37, by rule

Other programs on PTK2

ProgramCompanyFurthest phaseStudies
repotrectinibruleBristol-Myers Squibbphase 39

Studies

All 11 InxMed (Shanghai) leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07441174Solid Tumor Cancer · China2RecruitingFeb 28, 203192
NCT07174908Carcinoma, Non-Small-Cell Lung · China3RecruitingSep 2028400
NCT06030258Small Cell Lung Cancer Extensive Stage · China2Active, not recruitingNov 20, 2025120
NCT06014528Ovarian Cancer Recurrent · China2Active, not recruitingMar 24, 2027168
NCT05994131NSCLC · China2Active, not recruitingSep 20, 2025110
NCT05982522Solid Tumor2WithdrawnDec 31, 20260
NCT05830539Locally Advanced or Metastatic Solid Tumors · China2CompletedAug 31, 202468
NCT05827796Pancreatic Neoplasms · China2Active, not recruitingOct 11, 202570
NCT05551507Platinum-resistant Ovarian Cancer · China2Active, not recruitingMay 11, 2026150
NCT05327231Stomach Neoplasms · China1CompletedDec 3, 202133
NCT04109456Melanoma · United States, Australia1CompletedDec 20, 202451

How it is read

Names in the registry

  • “IN10018”, 8 entries
  • “BI 853520”, 2 entries
  • “IN10018 in combination with PLD”, 1 entry
  • “IN10018 in combination with RNK08954”, 1 entry
  • “IN10018 in combination with D-1553”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.